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Abstract
Germline TP53 pathogenic variants are rare but associated with a high risk of cancer; they are often identified in the
context of clinically diagnosed Li–Fraumeni syndrome predisposing to a range of young onset cancers including sar-
comas and breast cancer. The study aim was to conduct a detailed morphological review and immuno-phenotyping
of breast cancer arising in carriers of a germline TP53 pathogenic variant. We compared breast cancers from five
defined groups: (1) TP53 carriers with breast cancer (n = 59), (2) early onset HER2-amplified breast cancer, no
germline pathogenic variant in BRCA1/2 or TP53 (n = 55), (3) BRCA1 pathogenic variant carriers (n = 60);
(4) BRCA2 pathogenic variant carriers (n = 61) and (5) young onset breast cancer with no known germline patho-
genic variant (n = 98). Pathologists assessed a pre-agreed set of morphological characteristics using light micros-
copy. Immunohistochemistry (IHC) for HER2, ER, PR, p53, integrin alpha v beta 6 (αvβ6) integrin, α-smooth muscle
actin (α-SMA) and pSMAD2/3 was performed on tissue microarrays of invasive carcinoma. We confirmed a previ-
ously reported high prevalence of HER2-amplified, ductal no special type invasive breast carcinoma amongst known
TP53 germline pathogenic variant carriers 20 of 36 (56%). Furthermore we observed a high frequency of densely
sclerotic tumour stroma in cancers from TP53 carriers (29/36, 80.6%) when compared with non-carriers, 50.9%
(28/55), 34.7% (50/144), 41.4% (65/157), 43.8% (95/217) in groups 2–5 respectively. The majority of germline
TP53 gene carrier breast tumours had a high intensity of integrin αvβ6, α-SMA and pSMAD2/3 expression in the
majority of cancer cells. In conclusion, aggressive HER2 positive breast cancers with densely sclerotic stroma are
common in germline TP53 carriers. High levels of αvβ6 integrin, α-SMA and pSMAD2/3 expression suggest that the
dense stromal phenotype may be driven by upregulated transforming growth factor beta signalling.
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Introduction
The importance of functional wild-type p53 protein is
exemplified by the fact that somatic pathogenic
variants in TP53 are detected in more than 50% of all
cancer types, particularly more aggressive sub-types,
which constitute 28% of breast cancers [1,2]. Germline
TP53 pathogenic variants are rare and predispose to
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Society of Great Britain and Ireland and John Wiley & Sons Ltd.
J Pathol Clin Res; July 2019; 5: 189–198
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
early onset breast cancer which, in combination with
other tumour types such as malignant brain tumours
and sarcoma, is recognised clinically as a manifesta-
tion of Li–Fraumeni syndrome (LFS) [3,4]. TP53
encodes the p53 protein which has been referred to as
‘the guardian of the genome’ due to its crucial func-
tion in maintaining cellular homeostasis including cell
cycle arrest, apoptosis, angiogenesis, metabolism,
DNA damage and senescence in response to a number
of genotoxic stressors [5].
It has been recognised for over two decades that
breast cancers associated with BRCA1 pathogenic vari-
ants are predominantly triple receptor (ER, PR and
HER2) negative, high grade invasive ductal carcino-
mas with high numbers of tumour infiltrating lympho-
cytes (TILs) [6–10]. More recently we reported a
preliminary observation that germline TP53 patho-
genic variant carriers more commonly developed
HER2 positive invasive breast cancer when compared
to sporadic cases [9]. Our preliminary observation has
been confirmed by others [11–13]. In this study, we
describe an extended morphological and immunohisto-
chemical characterisation of a larger cohort of early
onset breast cancer patients with a germline TP53
pathogenic variant. We were interested to describe not
only the tumour features but also the characteristics of
the tumour microenvironment (TME), particularly the
stroma and presence or absence of TILs given the
growing interest in the therapeutic barriers and oppor-
tunities of the TME.
Methods
Patients and samples
Formalin fixed paraffin embedded (FFPE) breast can-
cer tissue blocks were used for this study.
Group 1: The COPE study (Cohort study of TP53
pathogenic variant carriers in early onset breast cancer)
acquired breast cancer tissue blocks from patients with
a known germline TP53 pathogenic variant and breast
cancer (multicentre research ethics committee approval
(09/H0501/85) (Table 1).
Group 2: Tissue blocks were selected from young
breast cancer (YBC) cases participating in the Prospec-
tive study of Outcomes in Sporadic versus Hereditary
breast cancer (POSH) for comparison [14]. POSH
cases were selected based on the following criteria –
tissue block available, no known pathogenic variant in
BRCA1, BRCA2 or TP53, invasive breast cancer
reported as HER2 positive with associated ductal car-
cinoma in situ (DCIS) (group 2, n = 55). Ethical
approval for POSH was granted in 2000 by South
West MREC (00/6/69).
H&E-stained sections for cases in groups 1 and
2 were assessed independently by two pathologists
(GM, MS) for a range of morphological features
(Table 1); discrepancies were resolved by a third
pathologist (AB).
Groups 3–5: Data were available from a previously
published morphological review comparing digital and
conventional (glass slide) microscopy reading amongst
cases from the POSH study [15]. This additional
dataset was therefore included for comparison of TP53
germline pathogenic variant carriers with other high risk
breast cancer susceptibility gene carriers and with young
onset non-carriers. Group 3 comprised known BRCA1
carriers, group 4 known BRCA2 carriers and group
5 YBC with no underlying germline pathogenic variant.
For groups 3–5, cases were randomly distributed
between 13 histopathologists who assessed pre-
specified morphological features using conventional
(glass slide) microscopy or a digital interface [15]. The
submitted reports from conventional microscopy were
extracted for each reported case. The POSH cases
were reported by more than one pathologist (1–3 per
case) so, for the purposes of statistical analyses, we
treated each report as a separate case. There were
138 pathologists’ reports for BRCA1 carriers, 157 for
BRCA2 and 217 for early onset non-carriers.
Morphological assessment
Morphological assessment was performed on 4 μm thick
sections cut using a microtome (Leica Biosystems, Milton
Keynes, Bucks, UK) from FFPE breast tumours. Sections
were mounted on Superfrost Plus™ Adhesion Micro-
scope Slides (ThermoFisher Scientific, Waltham, MA,
USA). Slides were stained using H&E on an automated
CoverStainer (Dako UK Ltd, Ely, Cambridge, UK).
Tissue microarray construction
H&E sections were reviewed and 1 mm cores of three
representative invasive and two representative in situ
areas were taken from the corresponding tissue blocks.
Cores were inserted into a new recipient paraffin block
using a tissue arrayer (Alphelys Minicore(R)3,
Langevin, France). 4 μm sections were cut from each
TMA using a microtome (Leica).
Immunohistochemistry
To further characterise breast cancer cases with
germline TP53 pathogenic variants (group 1), HER2,
ER, PR and p53 IHC was performed on TMA sections
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using an automated system. For HER2, ER and PR
IHC, the Roche Diagnostics Limited, West Sussex,
UK antibody with the Ventana Benchmark XT plat-
form and the Ultraview-Universal DAB detection Kit
were used. For p53 the Dako antibody was used with
Dako PT link for antigen retrieval, a Dako Autostainer
Link 48 staining platform and the Envision FLEX
detection system. IHC for integrin alpha v beta
6 (αvβ6), α-smooth muscle actin (α-SMA) and
pSmad2/3 was performed on TMA sections using a
method described previously [16]. For COPE cases
with HER2 positive results, in situ analysis was con-
ducted on whole tumour sections: dual hapten, dual
chromagen in situ hybridisation (DDISH) for HER2/
Chromosome 17 using the Roche Ventana INFORM
kit performed on the Ventana Ultra platform as per
manufacturer recommendations. All antibodies were
optimised using national diagnostic standards (UK
NEQAS central office, Sheffield, S Yorks, UK).
A further available dataset comprising ER, PR,
HER2 and p53 scores from 25 TMAs (1260 cases)
from the POSH cohort provided the typical frequency
of these markers in YBCs.
Scoring and statistical analysis
HER2 was scored as between 0 and 3 according
guidelines used in routine clinical practice based on
staining intensity, completeness of membrane expres-
sion and the proportion of cells stained [17]; a score of
either 2+ on IHC and a subsequent positive DDISH
test or 3+ on IHC alone are considered positive. ER
and PR were evaluated using the Allred scoring sys-
tem where positive was defined as a score of ≥3 [18].
p53 was scored using a semi-quantitative modified
McCarthy ‘H’ score; the modified scoring system gave
a maximum score of 7 based on the proportion of
cancer cells staining positive (1 = <25%, 2 = 25–50%,
3 = 50–75%, 4 = >75%) and the strength of staining
intensity (1 = weak, 2 = moderate, 3 = strong) [19,20].
αvβ6 and α-SMA were scored based on the strength of
staining intensity (1 = weak, 2 = moderate, 3 = strong)
as described by Marsh and colleagues for αvβ6 scoring
[16]. pSMAD2/3 was scored using the same method
as p53. Scoring was manual (two pathologists reaching
a consensus via simultaneous viewing of each core).
For pSMAD2/3, the digital pathology Halo Image
Analysis software was trained and used. Each core
was checked for tissue content, a classifier (evaluation
of tissue and background in the image) and a mark-up
(showing individual cell by cell scoring). Cores were
excluded where they were incomplete, contained nor-
mal tissue or where the software was unable to score
the material.
Summary statistics were used to describe the mor-
phological characteristics of the cases. IBM SPSS Sta-
tistics program (IBM United Kingdom Limited,
Portsmouth, Hampshire, UK) was used for Pearson
Chi-square, Fisher’s exact and Wilcoxon signed rank
tests. Pearson Chi-square was used when the number
of unpaired cases in each group was >5, Fisher’s exact
test was used when the number of unpaired cases in
each group was <5 and the Wilcoxon signed rank test
when testing statistical significance in paired data sets
with a skewed distribution of data.
Results
The COPE study recruited samples from 59 patients
with a confirmed germline TP53 pathogenic variant.
Fourteen cases had insufficient tumour for the study
and were excluded. Of the remaining 45 cases,
Table 1. Cohorts and recruitment eligibility: patient selection and eligibility for groups 1–5: TP53, BRCA1 and BRCA2 gene carriers,
HER2+and YBC with no underlying germline pathogenic variant
Cohort COPE POSH
Total no. of patients 45 2956
Group 1 2 3 4 5
Selection criterion Germline TP53 No germline pathogenic
variant HER2+
Germline BRCA1 Germline BRCA2 No germline
pathogenic variant YBC
No. of patients 45 55 60 61 98
No. of reads 45 55 138 157 217
Morphological review as
part of the COPE study*
✓ ✓
Morphological review as
part of the POSH study**
✓ ✓ ✓
TMAs ✓ ✓
*COPE morphology review (three breast histopathologists).
**POSH morphology review involving 13 breast histopathologists described in Shaw et al [22].
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36 contained invasive carcinoma and the other 9 con-
tained DCIS only. A total of 32 of 36 (88.9%) of inva-
sive carcinoma cases also had areas of DCIS. A total
of 41 of 45 (91.1%) of all cases contained DCIS with
40 of 41 (97.6%) of those cases scored as high grade.
Morphological assessment was included for
60 young onset cases with a germline BRCA1 patho-
genic variant (group 3), 61 young onset cases with a
germline BRCA2 pathogenic variant (group 4) and
98 young onset breast cancer cases (group 5) with no
identifiable germline high risk pathogenic variant
(BRCA1, BRCA2 or TP53) [21].
Morphological review of breast tumours derived in
germline TP53 carriers
The five young onset breast cancer cohorts were com-
pared. Descriptive summary statistics are provided in
Table 2.
A low level of lymphocytic infiltration was reported
in both TP53 carriers and HER2 positive cases
(absent/mild lymphocytic infiltration): TP53 30 of
36 (83.3%), HER2 positive 45 of 55 (81.8%). This
particularly contrasts with the BRCA1 carriers where
lymphocytic infiltration is a well-recognised feature
with a significantly lower proportion reported as hav-
ing absent or mild lymphocytic infiltrate, 72 of
138 (52.2%). BRCA2 carriers were similar to YBC,
non-carriers with 108 of 157 (68.8%) and 154 of
217 (71.0%) respectively. The tumour border was
more often infiltrative in the TP53 cohort, 36 of
36 (100.0%), and amongst HER2 positive cases, 52 of
55 (94.5%), compared to the BRCA1, BRCA2 and
YBC cases – 58 of 138 (42.0%), 93 of 157 (59.2%),
122 of 217 (56.2%) respectively. Vascular invasion
was more frequently reported as ‘present’ in cases
which were TP53 12 of 36 (33.3%) and HER2 posi-
tive 19 of 55 (34.5%) compared to BRCA1, BRCA2
and YBC – 20 of 138 (14.5%), 39 of 157 (24.8%) and
43 of 217 (19.8%) respectively. The most striking
morphological feature distinguishing the TP53
germline carriers was the presence of a densely scle-
rotic tumour stroma (Figure 1) reported in 29 of
36 (80.6%) of cases, compared with 28 of 55 (50.9%)
of young patients with HER2 positive breast cancer
with no germline TP53 pathogenic variant (p = 0.004)
and lower still in other groups; 50 of 138 BRCA1 car-
riers (36.2%, p < 0.001), 65 of 157 BRCA2 carriers
(41.4%, p < 0.001) and 95 of 217 in YBC (43.8%,
p < 0.001) (Table 3 and Figure 2).
Receptor status in TP53 carriers
Hormone receptor status was evaluated and compared
to available data in young onset breast cancer cohorts
between TP53 gene carriers (n = 36) and data avail-
able from the POSH cohort (n = 1260). TP53 gene
carriers were significantly more likely to be ER+/PR
+/HER2+ (p < 0.001) than in the POSH cohort
(Table 4).
Table 2. Morphological review comparing subgroups: morphological features in invasive breast tumour groups 1–5
Morphological feature Subgroup
Feature Grading TP53 HER2+ BRCA1 BRCA2 YBC
Tumour grade 1 2/36 (5.6%) 1/55 (1.8%) 7/138 (5.1%) 13/157 (8.3%) 35/217 (16.1%)
2 16/35 (44.4%) 26/55 (47.3%) 33/138 (23.9%) 80/157 (51.0%) 86/217 (40.0%)
3 18/36 (50.0%) 28/55 (50.9%) 98/138 (71.0%) 64/157 (40.8%) 96/217 (44.2%)
Tumour border Pushing 0/36 (0.0%) 3/55 (5.4%) 80/138 (58.0%) 63/157 (40.1%) 94/217 (43.3%)
Infiltrative 36/36 (100.0%) 52/55 (94.6%) 58/138 (42.0%) 93/157 (59.2%) 122/217 (56.2%)
Missing 0/36 (0.0%) 0/55 (0.0%) 0/138 (0.0%) 1/157 (0.6%) 1/217 (0.5%)
Lymphocytic infiltration Absent 14/36 (38.9%) 10/55 (18.2%) 13/138 (9.4%) 41/157 (26.1%) 58/217 (26.7%)
Mild 16/36 (44.4%) 35/55 (63.6%) 59/138 (42.8%) 67/157 (42.7%) 96/217 (44.2%)
Prominent 6/36 (16.7%) 10/55 (18.2%) 66/138 (47.8%) 48/157 (30.6%) 63/217 (29.0%)
Missing 0/36 (0.0%) 0/55 (0.0%) 0/138 (0.0%) 1/157 (0.6%) 0/217 (0.0%)
Vascular invasion Absent 24/36 (66.7%) 36/55 (65.4%) 118/138 (85.5%) 115/157 (73.2%) 168/217 (77.4%)
Present 12/36 (33.3%) 19/55 (34.6%) 20/138 (14.5%) 39/157 (24.8%) 43/217 (19.8%)
Missing 0/36 (0.0%) 0/55 (0.0%) 0/138 (0.0%) 3/157 (1.9%) 6/217 (2.8%)
Tumour stroma Cellular 1/36 (2.8%) 6/55 (10.9%) 26/138 (18.8%) 23/157 (14.6%) 33/217 (15.2%)
Sclerotic 29/36 (80.6%) 28/55 (50.9%) 50/138 (36.2%) 65/157 (41.4%) 95/217 (43.8%)
Desmoplastic 6/36 (16.7%) 20/55 (36.4%) 39/138 (28.3%) 34/157 (21.7%) 63/217 (29.0%)
Myxoid 0/36 (0.0%) 1/55 (1.8%) 3/138 (2.2%) 11/157 (7.0%) 6/217 (2.8%)
Other 0/36 (0.0%) 0/55 (0.0%) 19/138 (13.8%) 23/157 (14.6%) 20/217 (9.2%)
Missing 0/36 (0.0%) 0/55 (0.0%) 1/138 (0.7%) 1/157 (0.6%) 0/217 (0.0%)
Missing data refers to an unreported feature.
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Stromal markers: αvβ6 and α-SMA in TP53 carriers
A high number of TP53 carriers showed strong expres-
sion of p53 protein (≥5+: 69.4%, 25/36). Additionally,
moderate to high expression of the stromal marker
integrin αvβ6 was confirmed in 21 of 36 (58.3%) of
the invasive tumours of TP53 carriers in this study.
High expression of α-SMA (88.9%, 32/36) and
pSMAD2/3 (proportion 3/4: 30/36; 83.3%, intensity
2/3: 29/36; 80.6%) were confirmed in a high propor-
tion of tumours (Figure 3).
We explored whether the type of germline TP53
pathogenic variant present amongst the COPE cases
with invasive tumour altered the tumour phenotype.
Comparing missense (n = 24), with truncating (n = 12)
variants, excluding missing cases, a missense patho-
genic variant did appear more likely to be associated
with a sclerotic stroma (21/24, 87.5%) than a truncat-
ing pathogenic variant (8/12, 67.7%) although this was
Figure 1. Sclerotic stroma in TP53 carriers. (A) A magnified area of invasive tumour surrounded by sclerotic stroma. (B) (i)–(iv) Four
patient samples with invasive carcinoma surrounded by a sclerotic stroma. Images were taken on the Olympus Dotslide at an objective
magnification of ×20 (A) or ×10 (B). Scale bars represent 100 μm.





(% of cohort) Missing data
TP53 7/36 (19.4%) 29/36 (80.6%) 0/36 (0.0%)
HER2+ 27/55 (49.1%) 28/55 (50.9%) 0/55 (0.0%)
BRCA1 87/138 (63.0%) 50/138 (36.2%) 1/138 (0.7%)
BRCA2 91/157 (58.0%) 65/157 (41.4%) 1/157 (0.6%)
YBC 122/217 (56.2%) 95/217 (43.8%) 0/217 (0.0%)
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not statistically significant. HER2 overexpression was
slightly less frequent with germline missense (12/24,
50.0%) versus truncating (8/12, 66.7%) variants but
again the difference was not statistically significant.
Finally, we looked at the additional morphological
data for POSH cases with all four IHC markers
(Table 5). Amongst the 1260 young cancers from
which TMA IHC scores were available, aberrant p53
staining was present in 302. Of these, 65 also had
morphology evaluated in the previous study [22]. Scle-
rotic stroma was reported in 26 of 65 (40.0%) of
cases; 3 of 26 (11.5%) were also HER2-positive but
none were ER/PR/HER2 positive. Desmoplastic
stroma was reported in 21 of 65 (32.3%) of cases; 5 of
21 (23.8%) of these were also HER2+. Cellular stroma
was reported in 6 of 65 (9.2%) cases, all of which
were triple negative.
Amongst POSH cases 286 of 1260 (20.3%) were
HER2 amplified and of these just over half (145) were
ER/PR/HER2 positive (Table 4). We had information
about stromal morphology in 121 of 1260 cases with
complete IHC; 42 of 121 (34.7%) were HER2 posi-
tive, only 10 of these were also p53 positive. The
stroma in these 10 cases was reported as desmoplastic
(5), sclerotic (3), myxoid (2) and other (1). Only two
cases were positive for ER/PR/HER2 and p53.
Discussion
Patients with a germline TP53 pathogenic variant typi-
cally develop high grade (2 or 3), HER2 positive, infil-
trating ductal carcinoma, confirming our previously
reported observation and subsequent reports from
other groups [11–13]. The frequency of triple positiv-
ity (HER2, ER and PR) also appears significantly
higher in these patients than young onset cases in gen-
eral. A number of other morphological features are
similar between the cancers in germline TP53 patho-
genic variants and the HER2 positive early onset cases
from the POSH study. However, the high frequency of
breast tumours with densely sclerotic tumour stroma is
a novel observation in patients with a germline TP53
pathogenic variant. In comparison to sporadic HER2
amplified young onset breast cancers evaluated using
the same methodology, the frequency of densely scle-
rotic stroma was striking. In comparison, the fre-
quency of sclerotic stroma in sporadic HER2 positive
cases was more similar to the proportion reported in
other young onset cases; although we recognise that
the data from the other young onset groups was taken
from a previously reported study so may be less
directly comparable. Amongst sporadic HER2 ampli-
fied tumours with abnormal p53 expression, there was
no obvious excess of sclerotic stroma reported,
although numbers were relatively small.
In sporadic breast cancers, somatic TP53 mutations
are most frequent in triple negative and HER2 positive
tumours, less frequent in ER positive or HER2 nega-
tive cancers. Loss of function in the tumour tissue
occurs through inactivation or loss of both alleles.
Patients with breast cancer arising on a background of
an inherited TP53 pathogenic variant have already
developed the first hit along the molecular pathway to
carcinoma. It is possible that very early loss of TP53
function through somatic mutation in patients with an
inherited TP53 pathogenic variant may be the reason
Figure 2. TP53 carriers had a significantly higher proportion of
sclerotic tumour stroma. The bar chart shows the frequencies of
sclerotic stroma between cohorts. Statistics were performed on
TP53 carriers against each of the other groups using the Pearson
Chi-square test. Missing data were excluded.










HER2+/ER+/PR+ 13/36 (36.1%) 145/1260 (11.5%) <0.001
HER2+/ER+/PR− 1/36 (2.8%) 34/1260 (2.7%) ns
HER2+/ER−/PR+ 0/36 (0.0%) 10/1260 (0.8%) ns
HER2+/ER−/PR− 6/36 (16.7%) 97/1260 (7.7%) 0.023
HER2−/ER+/PR+ 7/36 (19.4%) 477/1260 (37.9%) ns
HER2−/ER+/PR− 2/36 (5.6%) 77/1260 (6.1%) ns
HER2−/ER−/PR+ 0/36 (0.0%) 27/1260 (2.1%) ns
HER2−/ER−/PR− 3/36 (8.3%) 393/1260 (31.2%) 0.008
Missing data 4/36 (11.1%) 0/1260 (0.0%)
Summary statistics for receptor status in invasive breast tumours within TP53
carriers and the YBC onset cohort POSH. Missing data refers to an unreported
feature.
*Fisher’s exact test.
194 Packwood K et al.
© 2019 The Authors. The Journal of Pathology: Clinical Research published by The Pathological
Society of Great Britain and Ireland and John Wiley & Sons Ltd.
J Pathol Clin Res July 2019; 5: 189–198
for the more frequent development of the sclerotic
stroma.
We explored this further by comparing the type of
inherited variant. Pathogenic missense variants in
TP53 often disrupt the function of the wild type pro-
tein (dominant negative effect); this leads to loss of
p53 function, even before the evolving cancer cell
develops loss or amplification of genomic material,
and often leads to a more severe Li–Fraumeni pheno-
type [23–28]. We hypothesise that a germline patho-
genic missense variant would be more likely to be
associated with a dense stromal reaction if this early
loss of function was the underlying driving factor.
Although numbers of cases were quite small, we did
observe a higher proportion of cases with dense scle-
rotic stroma amongst patients with missense patho-
genic variants, lending some support to this
hypothesis.
There is increasing evidence to suggest that the
intricate tumour-stromal interactions in the TME are
essential to driving tumour progression [16,22–26].
This complex system involves various cell types,
including fibroblasts, immune cells and endothelial
cells. The novel finding from this study was that breast
tumours derived from germline TP53 carriers typically
presented with an associated sclerotic tumour stroma.
Myofibroblasts are the cellular component of the
microenvironment that deposit the rich collagen layer
in a morphologically sclerotic stroma [27–30]. Myo-
fibroblasts are characterised by α-SMA expression
[31]. Tumours containing a high proportion of cancer-
associated fibroblasts (CAFs) positive for α-SMA,
have been associated with a poorer prognosis as a
result of increased migration, invasion, proliferation,
angiogenesis and inhibition of infiltrating lymphocytes
[16,22–25]. In TP53 carriers, high expression of
α-SMA in the surrounding stroma was confirmed in
88.9% of cases, suggesting that CAFs are playing a
key role.
A key pathway through which CAFs undergo trans-
formation and activate tumour-promoting processes is
via transforming growth factor beta (TGFβ) signalling.
One of the key mechanisms by which TGFβ is acti-
vated is through the expression of integrin αvβ6 on the
cell surface of tumour cells [27]. Integrin αvβ6
Figure 3. Examples of typical IHC for breast tumours arising in a mutant TP53 background. Tumours are typically ER (A), PR (B) and
HER2 (D) positive, show strong nuclear p53 staining (C) and are positive for markers of activated TGFβ signalling (F, αSMA; G, integrin
αvβ6; H, pSMAD2/3). A corresponding H&E stain is shown in (E).
Table 5. Expression of p53 and stromal markers in TP53 gene
carrier breast cancers
Stain Scoring TP53 gene carriers
p53 (0–7) 0–1 0/36 (0.0%)
2–4 7/36 (19.4%)
5+ 25/36 (69.4%)
Missing data 4/36 (11.1%)
Integrin αvβ6 Absent/low 11/36 (30.6%)
Moderate/high 21/36 (58.3%)
Missing data 4/36 (11.1%)
α-SMA Absent/low 1/36 (2.8%)
Moderate/high 32/36 (88.9%)
Missing data 3/36 (8.3%)




Staining intensity 1 2/36 (5.6%)
2 20/36 (55.6%)
3 9/36 (25.0%)
Missing data 5/36 (13.9%)
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expression was confirmed in 58.3% of invasive TP53
carrier tumours in this study, compared to only
15–16% of cases noted in a 2000 patient cohort
reported elsewhere [32]. PhosphoSMAD2/3 proteins
are activated through a phosphorylation cascade,
which forms the basis of initiated TGFβ signalling.
Activated pSMAD2/3 proteins migrate from the cyto-
plasm to the nucleus and initiate transcription and the
downstream deposition of collagen. Confirmation of
TGFβ signalling was evidenced by high levels of
pSMAD2/3 expression in breast cancers from TP53
carriers.
Patients with inherited TP53 pathogenic variants
develop a broad range of tumours including sarcomas
and childhood onset adrenocortical carcinomas; an
estimated 50% of women develop breast cancer, usu-
ally at young ages. Treatment with chemotherapy and
radiotherapy is thought to increase the risk of DNA
damage-induced late toxic effects, further increasing
the risk of developing second malignancies. The inva-
sive tumour characteristics in this group are typically
associated with poor outcomes, including a low level
of TILs in 83% of TP53 carriers, with an infiltrative
tumour border in 100% and vascular invasion in
33.3%. A potential mechanism by which TILs could
be being blocked from migrating towards the tumour
is the deposition of a collagen barrier by the CAFs
[33–38]. Furthermore, CAFs positive for α-SMA have
previously been reported to increase migration, inva-
sion, proliferation and angiogenesis [26,39,40].
Work by other groups has previously implicated
p53 in the upregulation of collagen [41]. Loss of p53
function was shown to upregulate TGFβ signalling
and as a consequence lead to the transcriptional activa-
tion of COL1A2 and collagen synthesis [41]. Murine
models heterozygous for loss of TP53 function
(p53+/−) developed an extensive proliferative stromal
reaction that was positive for α-SMA and S100A4, a
fibroblast marker [42]. Finally, multiple groups have
previously suggested that, through indirect cellular
contact, tumour cells can inhibit wild-type p53 activa-
tion and stimulate immunosuppression [43,44].
In summary, we have observed that breast tumours
arising in germline TP53 pathogenic variant carriers
are highly likely to be high grade, HER2 positive,
ER/PR positive tumours with an associated dense scle-
rotic tumour stroma. The early inactivation of wild-
type p53 may be one of the important mechanisms
leading to the activation of TGFβ via integrin αvβ6
and the development of breast cancers with many
adverse prognostic characteristics. Given the increased
risk of late toxicity from cytotoxic treatments (chemo-
therapy and radiotherapy) in germline TP53 gene
carriers, treatment with targeted agents including anti-
HER2 therapies such as trastuzumab (Herceptin) or
antibodies targeting the TGFβ signalling pathway may
be safer treatment options for breast cancer patients
found to carry a germline TP53 pathogenic variant.
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